Brokerages Set Metsera Inc. (NASDAQ:MTSR) PT at $59.00

Key Points

• Metsera Inc. (NASDAQ:MTSR) has received a consensus recommendation of "Buy" from five brokerages, with an average price target of $59.00.
• Bank of America and Guggenheim recently raised their price targets for Metsera shares, with Guggenheim setting it at $62.00 and Bank of America at $50.00.
• Several hedge funds have significantly increased their stakes in Metsera during the second quarter, indicating growing institutional interest in the company.

Metsera Inc. (NASDAQ:MTSR - Get Free Report) has been given a consensus rating of "Buy" by the five research firms that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $59.00.

A number of analysts recently weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Guggenheim lifted their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Bank of America boosted their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research note on Wednesday. Finally, Wall Street Zen upgraded Metsera from a "sell" rating to a "hold" rating in a report on Saturday, August 30th.

Metsera Stock Up 1.8%

Shares of NASDAQ:MTSR traded up $0.63 during midday trading on Friday, hitting $36.29. The company had a trading volume of 1,107,739 shares, compared to its average volume of 1,249,355. Metsera has a 12 month low of $12.30 and a 12 month high of $47.40. The firm has a fifty day simple moving average of $34.58 and a 200 day simple moving average of $28.65.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MTSR. Osaic Holdings Inc. raised its holdings in shares of Metsera by 45.5% during the second quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock worth $27,000 after acquiring an additional 296 shares during the period. BNP Paribas Financial Markets increased its holdings in Metsera by 100.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock worth $46,000 after purchasing an additional 800 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Metsera by 32.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company's stock valued at $122,000 after purchasing an additional 1,056 shares during the period. Prudential Financial Inc. boosted its position in shares of Metsera by 7.9% during the second quarter. Prudential Financial Inc. now owns 16,070 shares of the company's stock worth $457,000 after buying an additional 1,170 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Metsera by 25.0% during the second quarter. New York State Common Retirement Fund now owns 6,000 shares of the company's stock worth $171,000 after buying an additional 1,200 shares during the period.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.